Normal Saline

Normal Saline

Form: Intravenous (IV) Infusion Solutions

Strength: 0.9% w/v (9 mg/mL sodium chloride)

Reference Brands: Normal Saline(Generics)

Category: Critical Care

Normal Saline (0.9% Sodium Chloride) and Ringer’s Lactate (RL) are widely used isotonic IV fluids essential for fluid resuscitation, electrolyte balance, and critical care. Available in 100 mL to 1000 mL infusion bags, these sterile solutions are manufactured by leading pharma brands like Baxter, B. Braun, and Fresenius Kabi across the US and EU. Normal Saline is preferred for volume replacement and drug dilution, while RL is ideal for trauma, burns, and acidosis. Pharma B2B platforms ensure consistent bulk supply of NS and RL IV solutions to hospitals, emergency services, and intensive care units worldwide, maintaining continuous care standards.

Get Enquiry Back to Listing
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'

The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.

Related Products

Glucagon

Strength: 1 mg lyophilized powder for reconstitution (IM/SC/IV)

Form: Intramuscular (IM), Subcutaneous (SC), and Intravenous (IV) injection

Reference Brands: Glucagen®, Gvoke®,Baqsimi®(US); Glucagen® Hypokit(EU)

View Details Get Enquiry
Insulin (Iv)

Strength: 100 units/mL (U-100) in 10 mL vials

Form: Intravenous (IV) solution

Reference Brands: Humulin® R, Novolin® R(US); Actrapid®, Humulin® R, Insuman® Rapid(EU)

View Details Get Enquiry
Flumazenil

Strength: 0.1 mg/mL in 5 mL or 10 mL vials

Form: Intravenous (IV) injection

Reference Brands: Romazicon®(US), Anexate®(EU)

View Details Get Enquiry
Naloxone

Strength: 0.4 mg/mL in 1 mL/10 mL vials, 1 mg/mL in 2 mL prefilled syringes

Form: Intravenous (IV) injection/IM/SQ

Reference Brands: Narcan® (US); Narcan® (EU)

View Details Get Enquiry

Subscribe to Our Newsletter

Stay updated on pharma trends and marketplace opportunities.

We use cookies to ensure you get the best experience. Learn more